Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Paroxetine with anti-competitive conduct.....
View:
Post by happyretirement on Mar 07, 2017 9:11am

Paroxetine with anti-competitive conduct.....

Similar SO with outcome.....

https://www.gov.uk/government/news/cma-fines-pharma-companies-45-million


The total penalty in respect of GUK is £5,841,286 for which Merck KGaA is

liable for £5,841,286; and of that amount Generics (UK) Limited is jointly

and severally liable, with Merck KGaA, for £2,732,765.

In respect of GUK’s infringement, total fines of £5,841,286 have been

imposed on Merck KGaA (GUK’s former parent) and GUK.

 

The statement of objections is additionally addressed to Cinven as the

ultimate parent company of Concordia International (Jersey) Limited from

1 January 2013 until 20 October 2015.
Comment by happyretirement on Mar 07, 2017 9:23am
Discussed the article with Billy Kenber yesterday and sent him the Paroxetine article to compare..... in summary if guilt is found..... Contains Parliamentary information licensed under the Open Parliament Licence v3.0. The CMA has found that GSK’s agreements with each of GUK and Alpharma infringed the competition law prohibition on anti-competitive agreements. The CMA has also found that GSK’s ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities